1Jonsson R, Bowman SJ, Gordon TP. Sjogren's syndrome //Koopman WJ. Arthritis and allied conditions. 15th ed. Phil-adelphia: Lippincott Williams & Wilkins, 2005: 1681-1705.
2Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome :a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis, 2002, 61: 554-558.
3Theander E,Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis, 2006, 65: 796-803.
4Lazarus MN, Robinson D, Mak V, et al. Incidence of cancer in a cohort of patients with primary Sjogren's syndrome. Rheumatology (Oxford), 2006, 45: 1012-1015.
5Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum, 2002, 46: 741-747.
6Kassan SS,Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sieea syndrome. Ann Intern Med, 1978, 89: 888- 892.
7Valesini G, Priori R, Bavoillot D, et al. Differential risk of non- Hodgkin's lymphoma in Italian patients with primary Sjogren's syndrome. J Rheumatol, 1997, 24: 2376.
8Pertovaara M, Pukkala E, Laippala P, et al. A longitudinal cohort study of Finnish patients with primary Sjogren's syndrome: clinical, immunological, and epidemiologic aspects. Ann Rheum Dis, 2001, 60: 467.
9Jonsson R, Nginamau E, Szyszko E, et al. Role of B cells in Sjogren's syndrome-from benign lymphoproliferation to overt malignancy. Front Biosci, 2007, 12: 2159-2170.
10Salomonsson S, Jonsson MV, Skarstein K, et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum, 2003, 48: 3157-3201.
